Share dropped a whopping 44% in a single day in mid-December, though they’ve since recovered roughly 22%. at the J.P. Morgan Healthcare Conference ? Or is the recent rise a signal that PacBio is turning a corner? It’s time for a closer look.

The reaction to the termination of a contract with Swiss pharma giant Roche last month was severe. It looks like value-minded investors are taking advantage of the stock’s bargain bin price and perhaps salivating over the increased attractiveness of the company as an acquisition following the deal’s termination.